Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

EURAS EUropean network for neurodevelopmental RASopathies

Coordinator
Universitatsklinikum Erlangen, Germany
Runs
1 June 2023 to 31 May 2027
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
17 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101080580

What the project is doing

In the project's own words, from its summary on CORDIS.

Cardio-facio-cutaneous syndrome, Costello syndrome and SYNGAP1-related encephalopathy are rare neurodevelopmental RASopathies manifesting with severe intellectual disability, seizures and autism spectrum disorder. These symptoms are underdiagnosed and lack approved therapeutic options. EURAS aims to develop new effective therapies and operative disease management for RASopathies. With strong support of patient organizations from 13 countries, a new patient report-based registry for stratification of patient cohorts and evaluation of treatments will be implemented.

To clarify the pathophysiology of RASopathies and to identify cellular/molecular “disease signatures” as biomarkers for drug screening and for therapy validation, EURAS will generate new and employ existing disease models. Phenotypical screenings of drug libraries assisted by automated high-resolution, high-content pipelines will be conducted on differentiated, electrically active patient iPSC-derived neurons. Preclinical proof-of-concept trials with repurposed drugs, antisense oligonucleotides and motor-cognitive training will be performed to achieve reversal of seizures and autistic behavioural traits in animal models.

To provide patients with less invasive treatments, new technologies for efficient drug delivery of treatments to the brain will be developed and validated. Finally, EURAS establishes Europe-wide patient association to improve awareness and exchange between affected families and to foster their access to knowledge and therapies. With all these measures, EURAS delivers new effective therapies and set the frame for early and accurate diagnosis of neurological symptoms in RASopathies, which are not available at present.

Moreover, some results of EURAS will be widely transferable, fostering development of therapies even for unrelated diseases. Thus, EURAS will sustainably improve the lives of affected people and strengthen expertise of health systems in Europe and worldwide.

Topics

Who is involved

OrganisationCityCountryRole
Universitatsklinikum ErlangenErlangenGermanyCoordinator
Ait Austrian Institute of Technology GmbHWienAustriaParticipant
Paracelsus Medizinische Privatuniversitat Salzburg - PrivatstiftungSalzburgAustriaParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eVMunchenGermanyParticipant
Neuway Pharma GmbHBonnGermanyParticipant
Otto-Von-Guericke-Universitaet MagdeburgMagdeburgGermanyParticipant
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyParticipant
Syngap Elternhilfe E. VKrefeldGermanyParticipant
Universitaet UlmUlmGermanyParticipant
Zentralinstitut Fuer Seelische GesundheitMannheimGermanyParticipant
Universidad De MalagaMalagaSpainParticipant
Turun YliopistoTurkuFinlandParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Ist-Id Associacao Do Instituto Superior Tecnico Para a Investigacao E O DesenvolvimentoLisboaPortugalParticipant
The University of EdinburghEdinburghUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI